You are a senior ethicist and mediator. A pharmaceutical company has developed a life-saving drug with a 90% success rate, but the remaining 10% of patients suffer fatal side effects. The company wants immediate approval. The patient advocacy group demands a delay for further testing. Investors are threatening to pull funding, which would end the project entirely. Draft a step-by-step negotiation and ethical resolution strategy that addresses the utilitarian need for the drug, the deontological rights of the patients at risk, and the fiduciary duties to the investors. Provide the final recommendation with a detailed justification.